Company / Shareholders' Equity
Cytek Biosciences, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$341.7M
FY2025
5-year range
-$41.7M / $425.5M
FY2021-FY2025
Trend
-13.6%
vs FY2024
Sector context
#122 of 161
Health Care
What the data says
Cytek Biosciences, Inc.'s shareholders' equity of $342M is lower than 76% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 6 years, ranging from -$42M in FY2021 to $426M in FY2022.
Based on SEC 10-K filings.
$342M in FY2025 with a 3-year CAGR of -7.1%.
Declined from $393M to $342M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -7.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 161This company $341.7M Sector average $5.1B
▼
-93.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -7.1%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 13.6% year-over-year.
- Ranks #122 out of 161 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $341.7M | -13.6% |
| FY2024 | $395.7M | +0.7% |
| FY2023 | $393.1M | -7.6% |
| FY2022 | $425.5M | +1120.5% |
| FY2021 | -$41.7M | -160.2% |
| FY2020 | -$16.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026